Health
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]
Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]
Read More
Patient advocacy groups urge U.S. court to halt overseas prescription drug operations
In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York. Spencer Platt | Getty Images News | Getty Images A coalition of patient advocacy groups is urging a federal court to halt the practices of third-party companies that buy drugs from countries outside the FDA-regulated […]
Read More
CNBC launches CNBC Cures to help 30 million Americans with rare diseases
Thirty million. It’s a big number. Maybe not in the context of business news, where we usually talk about company valuations that are in the billions, or even trillions. But when we’re talking about people, 30 million is a very big number. Thirty million is the number of people that the National Organization of Rare […]
Read More
CNBC’s Becky Quick details daughter’s rare disease journey
I’ve spent the last 25 years in front of the camera here at CNBC, and people have gotten to know a lot about me. What they don’t know, though, is probably the most important part: My family. And our family is a happy one. But we are also unique, and we have our struggles. Our 9-year-old […]
Read More
OpenAI launches ChatGPT Health to connect user medical records, wellness apps
OpenAI CEO Sam Altman attends an event to pitch AI for businesses in Tokyo, Feb. 3, 2025. Kim Kyung-hoon | Reuters OpenAI on Wednesday announced ChatGPT Health, which will allow users to securely connect their medical records and wellness apps to the artificial intelligence chatbot. ChatGPT Health is not intended for diagnosis and treatment, and […]
Read More
RFK Jr. announces new nutrition guidelines, pushing more protein and less processed food
Secretary of Health and Human Services Robert F. Kennedy Jr. speaks during the daily briefing in the Brady Briefing Room of the White House in Washington, DC, on Jan. 7, 2026. Mandel Ngan | AFP | Getty Images Health and Human Services Secretary Robert F. Kennedy Jr. and Agriculture Secretary Brooke Rollins on Wednesday shared […]
Read More
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity […]
Read More
2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]
Read More